"I have never seen this much enthusiasm collectively for a class of drugs before," Asthika Goonewardene, a London-based analyst at Bloomberg Industries, tells the reporters. "This is essentially what we call a land grab. There's opportunity, and everybody is going out to find what that opportunity is."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.